CARRIE CALES: Open Payments
NPI 1043560683 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,504 in 141 payments from 25 companies in 2025. Trend: 2023 $119 · 2024 $2,304 · 2025 $2,504
Food & beverage: $2,504
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $557 |
| Janssen Biotech, Inc. | 13 | $280 |
| PFIZER INC. | 13 | $260 |
| GENZYME CORPORATION | 5 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $142 |
| QOL Medical, LLC | 7 | $142 |
| Phathom Pharmaceuticals, Inc. | 19 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $98 |
| Ferring Pharmaceuticals Inc. | 4 | $87 |
| Madrigal Pharmaceuticals | 4 | $79 |
Products named: TREMFYA, DUPIXENT, LINZESS, RINVOQ, VELSIPITY, Sucraid, VOQUEZNA, XELJANZ.
Industry payments across OH — which companies pay providers there.
